Le Lézard
Classified in: Health
Subjects: CCA, FVT

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024


BOSTON, Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 8, 2024.

The call can be accessed via teleconference at: Q3 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/unynzc8w 

A replay of the conference call and webcast will be available for one year beginning on February 8, 2024 at 11:00 am ET using the conference call webcast link provided in this press release.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts: 



Olga Guyette, Sr. Director-Investor Relations & Treasury   


David Trenk, Manager-Investor Relations

(781) 356-9763     


(203) 733-4987

[email protected]     


[email protected] 




Media Contact: 



Josh Gitelson, Director-Global Communications



(781) 356-9776



[email protected] 

SOURCE Haemonetics Corporation


These press releases may also interest you

at 20:05
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

More news about Health...


News published on and distributed by: